• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.

作者信息

Knudsen Jakob Schöllhammer, Thomsen Reimar Wernich, Pottegård Anton, Knop Filip Krag, Sørensen Henrik Toft

机构信息

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

出版信息

Diabetes Care. 2018 Sep;41(9):e133-e135. doi: 10.2337/dc18-0999. Epub 2018 Jul 12.

DOI:10.2337/dc18-0999
PMID:30002200
Abstract
摘要

相似文献

1
Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.胰高血糖素样肽-1受体激动剂利拉鲁肽的随机临床试验患者与真实世界起始使用者之间的差异
Diabetes Care. 2018 Sep;41(9):e133-e135. doi: 10.2337/dc18-0999. Epub 2018 Jul 12.
2
Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.胰高血糖素样肽-1受体激动剂利拉鲁肽对糖耐量正常患者银屑病无效——一项随机安慰剂对照试验
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629. Epub 2014 Aug 20.
3
Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.胰高血糖素样肽-1受体激动剂介导的心脏纤维化减轻的分子和细胞机制
Diab Vasc Dis Res. 2016 Jan;13(1):56-68. doi: 10.1177/1479164115605000. Epub 2015 Sep 25.
4
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.利拉鲁肽治疗对 2 型糖尿病胰高血糖素分泌的影响：来自 LIBRA 试验的观察。
J Clin Endocrinol Metab. 2015 Oct;100(10):3702-9. doi: 10.1210/jc.2015-2725. Epub 2015 Jul 31.
5
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.利拉鲁肽对射血分数降低的晚期心力衰竭患者临床稳定性的影响：一项随机临床试验。
JAMA. 2016 Aug 2;316(5):500-8. doi: 10.1001/jama.2016.10260.
6
Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.利拉鲁肽：用于成年 2 型糖尿病患者的综述。
Drugs. 2014 Dec;74(18):2161-74. doi: 10.1007/s40265-014-0321-6.
7
Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.利用胰高血糖素样肽-1受体激动剂进行超重和肥胖的药物治疗。
Obes Rev. 2017 Jan;18(1):86-98. doi: 10.1111/obr.12465. Epub 2016 Sep 16.
8
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.利拉鲁肽是一种胰高血糖素样肽-1受体激动剂，它通过涉及β-连环蛋白的磷酸肌醇3-激酶（PI3K）/蛋白激酶B（AKT）、细胞外信号调节激酶（ERK）1/2和环磷酸腺苷/蛋白激酶A（PKA）信号通路，促进MC3T3-E1细胞的成骨增殖和分化。
Exp Cell Res. 2017 Nov 15;360(2):281-291. doi: 10.1016/j.yexcr.2017.09.018. Epub 2017 Sep 15.
9
Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.1型糖尿病闭环系统中辅助利拉鲁肽与胰岛素对比胰岛素单药治疗：一项随机开放标签交叉设计试验
J Diabetes Sci Technol. 2016 Aug 22;10(5):1108-14. doi: 10.1177/1932296816647976. Print 2016 Sep.
10
The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice.5-羟色胺 5-HT2C 和黑皮质素-4 受体对胰高血糖素样肽 1 和利拉鲁肽（一种胰高血糖素样肽 1 受体激动剂）在小鼠中的饱腹信号转导的贡献。
Biochem Biophys Res Commun. 2011 Jul 29;411(2):445-8. doi: 10.1016/j.bbrc.2011.06.175. Epub 2011 Jul 2.

引用本文的文献

1
Liraglutide inhibits the development of colorectal cancer by regulating TGF-β/Smad3 signaling pathway and affecting epithelial-mesenchymal transition.利拉鲁肽通过调节TGF-β/Smad3信号通路和影响上皮-间质转化来抑制结直肠癌的发展。
Discov Oncol. 2025 Jul 18;16(1):1371. doi: 10.1007/s12672-025-03223-6.
2
Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial.利拉鲁肽的真实世界心血管效应：LEADER试验的可推广性分析
medRxiv. 2025 May 30:2025.05.12.25327466. doi: 10.1101/2025.05.12.25327466.
3
Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.
利拉鲁肽在2型糖尿病中的疗效：来自葡萄牙患者真实世界队列的见解。
Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121.
4
Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway.胰高血糖素样肽-1受体激动剂通过调节PI3K/AKT/mTOR信号通路对大肠癌细胞生物学行为的影响
Front Pharmacol. 2022 Aug 10;13:901559. doi: 10.3389/fphar.2022.901559. eCollection 2022.
5
Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300).控制接受甘精胰岛素 300U/mL（Gla-300）治疗的 1 型糖尿病患者的血糖变异性。
BMJ Open Diabetes Res Care. 2022 Aug;10(4). doi: 10.1136/bmjdrc-2022-002898.
6
Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis.直接口服抗凝剂在肥胖房颤成年患者中的有效性：系统评价的系统评价与荟萃分析
Front Cardiovasc Med. 2021 Oct 8;8:732828. doi: 10.3389/fcvm.2021.732828. eCollection 2021.
7
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?在真实世界环境中，有多少 2 型糖尿病患者符合胰岛素甘精 300U/ml 随机对照试验的入选标准？
Diabetes Obes Metab. 2021 Mar;23(3):838-843. doi: 10.1111/dom.14264. Epub 2020 Dec 18.
8
Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.在现实临床实践中起始使用胰高血糖素样肽-1受体激动剂（GLP-1 RA）或基础胰岛素后的血糖控制：一项回顾性、观察性、纵向队列研究
Diabetes Ther. 2020 Nov;11(11):2629-2645. doi: 10.1007/s13300-020-00905-y. Epub 2020 Sep 9.